Esperion Therapeutics (ESPR)

Executive Summary

Esperion Therapeutics is a commercial-stage biopharmaceutical company focused on developing oral, non-statin therapies for LDL cholesterol reduction. Its approved products, NEXLETOL and NEXLIZET (bempedoic acid with or without ezetimibe), address a significant unmet need in patients with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional LDL-C lowering, particularly those intolerant to statins. The company has a robust pipeline of 22 drug candidates exploring fixed-dose combinations and complementary mechanisms to target broader lipid and cardiometabolic risk factors. Key clinical data, including the CLEAR Outcomes trial, support the potential for expanded indications and label enhancements. With a growing commercial footprint in the U.S. and international partnerships, Esperion is positioned for continued revenue growth. However, competition from established PCSK9 inhibitors and generic statins, along with pricing pressures, remain challenges. The upcoming catalysts could further de-risk the pipeline and drive shareholder value.

Upcoming Catalysts (preview)

• Q3 2026FDA decision on supplemental NDA for primary prevention indication in cardiovascular disease75% success
• Q4 2026Phase 2 data readout for fixed-dose combination of bempedoic acid with atorvastatin60% success
• TBDPotential licensing or partnership agreement for ex-U.S. commercialization rights50% success